Efficacy and Safety of Netupitant and Palonosetron Hydrochloride Capsules in Preventing Nausea and Vomiting Induced by Radiochemotherapy in Head and Neck Squamous Cell Carcinoma

Exclusion Criteria

• •1. Recurrent and metastatic head and neck tumors;
• •2. Previously underwent tumor resection surgery for treatment;
• •3. Patients with platinum drug intolerance;
• •4. Receiving any known or potential antiemetic medication within 24 hours prior to the first day, or experiencing symptoms of vomiting, retching, or mild nausea within 24 hours prior to the first day;
• •5. Take NK1（neurokinin-1） receptor antagonists or any study medication within 4 weeks before the start of the experiment;
• •6. Use CYP3A4 inducer within 4 weeks before chemotherapy, and use CYP3A4 substrate or strong or moderate CYP3A4 inhibitor within 1 week;
• •7. Serious cardiovascular, pulmonary, diabetes, mental and other diseases;
• •8. Pregnant or lactating women, patients with fertility who are unwilling or unable to take effective contraceptive measures;
• •9. Drug and/or alcohol abuse;
• •10. Hypocalcemia or any other condition that may cause vomiting;
• •11. There are significant factors that affect the absorption of oral medication, such as chronic diarrhea and intestinal obstruction;
• •12. The subject has allergic reactions to Netopitam Palonosetron capsules or any of their excipients;
• •13. Within 30 days prior to the baseline visit, the subject participated in another clinical study and used any exploratory drugs or devices; Allow participation in observational research;
• •14. The researcher determines other situations that may affect the progress of clinical research and the determination of research results.